FDA News

Latest News

FDA Decisions to Watch in Q4 2024 thumbnail
5 FDA Decisions to Watch in Q4 2024

October 4th 2024

A review of 5 highly anticipated FDA decisions expected by year-end, including acoramidis for ATTR-CM, olezarsen for FCS, sotagliflozin for T1D and CKD, and more.

FDA black and white logo | Credit: US Food and Drug Administration
FDA Approves Exact Sciences’ Cologuard Plus Test for Colorectal Cancer Screening

October 4th 2024

Aldeyra Resubmits New Drug Application for Reproxalap For Dry Eye Disease | Image Credit: US Food and Drug Administration
Aldeyra Resubmits New Drug Application for Reproxalap for Dry Eye Disease

October 3rd 2024

FDA black and white logo | Credit: US Food and Drug Administration
Denifanstat Receives Breakthrough Therapy Designation for Noncirrhotic MASH

October 1st 2024

TransCon hGH Aims for FDA Label Expansion for Adult Growth Hormone Deficiency| Image Credit: US Food and Drug Administration
TransCon hGH Aims for FDA Label Expansion for Adult Growth Hormone Deficiency

September 30th 2024

Video Interviews
Podcasts
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.
Thumbnail featuring podcast hosts and logo for Diabetes Dialogue

More News

© 2024 MJH Life Sciences

All rights reserved.